Zahra Foruzandeh

Dr. Zahra Foruzandeh

Genetics, Academic Center for Education, Culture and Research (ACECR), Tabrīz, Āz̄arbāyjān-e Sharqī, Iran
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2021 in Cellular & Molecular Biology Letters
Verified
Journal Article
Open access
PDF file
ZFZahra Foruzandeh
Zahra Foruzandeh
FZFatemeh Zeinali-Sehrig
Fatemeh Zeinali-Sehrig
KNKazem Nejati
Kazem Nejati
DRDara Rahmanpour
Dara Rahmanpour
FPFariba Pashazadeh
Fariba Pashazadeh
MAMohammad Reza Alivand
Mohammad Reza Alivand
More powerful prognostic and diagnostic tools are urgently needed for identifying and treating ovarian cancer (OC), which is the most fatal malignancy in women in developed countries. Circular RNAs (circRNAs) are conservative and stable looped molecules that can regulate gene expression by competing with other endogenous microRNA sponges. This discovery provided new insight into novel methods for regulating genes that are involved in many disorders and cancers. This review focuses on the dysregulated expression of circRNAs as well as their diagnostic and prognostic values in OC. We found that studies have identified twenty-one downregulated circRNAs and fifty-seven upregulated ones. The results of these studies confirm that circRNAs might be potent biomarkers with diagnostic, prognostic and therapeutic target value for OC. We also consider the connection between circRNAs and OC cell proliferation, apoptosis, metastasis, and chemotherapy resistance and sensitivity.

18 June 2016 in Acta Ophthalmologica
Verified
Journal Article
Closed access
PDF file
MBMortaza Bonyadi
Mortaza Bonyadi
ZFZahra Foruzandeh
Zahra Foruzandeh
TMTahereh Mohammadian
Tahereh Mohammadian
NFNikou Fotouhi
Nikou Fotouhi
MSMasoud Soheilian
Masoud Soheilian
MYMehdi Yaseri
Mehdi Yaseri

8 May 2023 in BMC Research Notes
Verified
Journal Article
Open access
PDF file
ZFZahra Foruzandeh
Zahra Foruzandeh
MAMohammad Reza Alivand
Mohammad Reza Alivand
MGMehdi Ghiami-Rad
Mehdi Ghiami-Rad
MZMohammad Zaefizadeh
Mohammad Zaefizadeh
SGSaeid Ghorbian
Saeid Ghorbian
Objectives: Breast cancer (BC) is one of the most common cancers with a high mortality rate in women worldwide. The advantages of early cancer diagnosis are apparent, and it is a critical factor in increasing the patient’s life and survival. According to mounting evidence, microRNAs (miRNAs) may be crucial regulators of critical biological processes. miRNA dysregulation has been linked to the beginning and progression of various human malignancies, including BC, and can operate as tumor suppressors or oncomiRs. This study aimed to identify novel miRNA biomarkers in BC tissues and non-tumor adjacent tissues of patients with BC. Microarray datasets GSE15852 and GSE42568 for differentially expressed genes (DEGs) and GSE45666, GSE57897, and GSE40525 for differentially expressed miRNAs (DEMs) retrieved from the Gene Expression Omnibus (GEO) database were analyzed using “R” software. A protein-protein interaction (PPI) network was created to identify the hub genes. MirNet, miRTarBase, and MirPathDB databases were used to predict DEMs targeted genes. Functional enrichment analysis was used to demonstrate the topmost classifications of molecular pathways. The prognostic capability of selected DEMs was evaluated through a Kaplan-Meier plot. Moreover, the specificity and sensitivity of detected miRNAs to discriminate BC from adjacent controls were assessed by area under the curve (AUC) using the ROC curve analysis. In the last phase of this study, gene expression on 100 BC tissues and 100 healthy adjacent tissues were analyzed and calculated by using the Real-Time PCR method. Results: This study declared that miR-583 and miR-877-5p were downregulated in tumor samples in comparison to adjacent non-tumor samples (|logFC|< 0 and P ≤ 0.05). Accordingly, ROC curve analysis demonstrated the biomarker potential of miR-877-5p (AUC = 0.63) and miR-583 (AUC = 0.69). Our results showed that has-miR-583 and has-miR-877-5p could be potential biomarkers in BC.

6 March 2023 in Egyptian Journal of Medical Human Genetics
Verified
Journal Article
Open access
PDF file
MRMaryam Ranjbar
Maryam Ranjbar
SHSamaneh Heydarzadeh
Samaneh Heydarzadeh
MKMahmoud Shekari Khaniani
Mahmoud Shekari Khaniani
ZFZahra Foruzandeh
Zahra Foruzandeh
FSFarhad Seif
Farhad Seif
MAMohammadReza Alivand
MohammadReza Alivand
Long noncoding RNAs are characterized as noncoding transcripts longer than 200 nucleotides in response to a variety of functions within the cells. They are involved in almost all cellular mechanisms so as epigenetics. Given that epigenetics is an important phenomenon, which participates in the biology of complex diseases, many valuable studies have been performed to demonstrate the control status of lncRNAs and epigenetics. DNA methylation and histone modifications as epigenetic mechanisms can regulate the expression of lncRNAs by affecting their coding genes. Reciprocally, the three-dimensional structure of lncRNAs could mechanistically control the activity of epigenetic-related enzymes. Dysregulation in the mutual interaction between epigenetics and lncRNAs is one of the hallmarks of cancer. These mechanisms are either directly or indirectly involved in various cancer properties such as proliferation, apoptosis, invasion, and metastasis. For instance, lncRNA HOTAIR plays a role in regulating the expression of many genes by interacting with epigenetic factors such as DNA methyltransferases and EZH2, and thus plays a role in the initiation and progression of various cancers. Conversely, the expression of this lncRNA is also controlled by epigenetic factors. Therefore, focusing on this reciprocated interaction can apply to cancer management and the identification of prognostic, diagnostic, and druggable targets. In the current review, we discuss the reciprocal relationship between lncRNAs and epigenetic mechanisms to promote or prevent cancer progression and find new potent biomarkers and targets for cancer diagnosis and therapy.

10 May 2022 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
ZFZahra Foruzandeh
Zahra Foruzandeh
DDDavood Ghavi Dorabadi
Davood Ghavi Dorabadi
FSFarzaneh Sadeghi
Farzaneh Sadeghi
FZFatemeh Zeinali-Sehrig
Fatemeh Zeinali-Sehrig
MZMohammad Zaefizadeh
Mohammad Zaefizadeh
MAMohammad Reza Alivand
Mohammad Reza Alivand

1 June 2023 in Pathology - Research and Practice
Verified
Journal Article
Closed access
AEAmir Ebrahimi
Amir Ebrahimi
SDSima Mansoori Derakhshan
Sima Mansoori Derakhshan
DGDavood Ghavi
Davood Ghavi
ZFZahra Foruzandeh
Zahra Foruzandeh
SHSolmaz Hashemi
Solmaz Hashemi